Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma

Authors: Verena Ruhlmann, Thorsten D. Poeppel, Johannes Veit, James Nagarajah, Lale Umutlu, Thomas K. Hoffmann, Andreas Bockisch, Ken Herrmann, Wolfgang Sauerwein

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The aim of this study was to evaluate the value of 18F–FDG PET/CT (PET/CT) and MRI for local and/or whole-body restaging of adenoid cystic carcinoma of the head and neck (ACC).

Methods

Thirty-six patients with ACC underwent conventional MRI of the head and neck and a whole-body PET/CT and were analysed with regards to detection of a local tumor recurrence, lymph node or distant metastases. A consensus interpretation of all available imaging data was used as reference standard. Sensitivity, specificity, diagnostic accuracy, positive and negative predictive values were calculated for MRI and PET/CT.

Results

The sensitivity of PET/CT and MRI was 96% (89%), specificity 89% (89%), PPV 96% (96%), NPV 89% (73%) and accuracy 94% (89%) for detection of local tumors. Additionally, PET/CT revealed lymph node metastases in one patient and distant metastases in 9/36 patients. In three patients secondary primaries were found.

Conclusions

Whole-body PET/CT in addition to MRI of the head and neck improves detection of local tumour and metastastic spread in ACC.
Literature
1.
Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005.
2.
Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Rad Oncol. 1995;32:619–26.CrossRef
3.
Chummun S, McLean NR, Kelly CG, Dawes PJDK, Fellows S, Meikle D, et al. Adenoid cystic carcinoma of the head and neck. Br J Plast Surg. 2001;54:476–80.CrossRefPubMed
4.
Dubergé T, Bénézery K, Resbeut M, Azria D, Minsat M, Ellis S, et al. Carcinomes adénoïdes kystiques ORL : étude rétrospective multicentrique de 169 cas. Cancer/Radiothérapie. 2012;16:247–56.CrossRef
5.
Schulz-Ertner D, Nikoghosyan A, Didinger B, Münter M, Jäkel O, Karger CP, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005;104:338–44.CrossRefPubMed
6.
Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol. 2001;59:161–7.CrossRefPubMed
7.
Prott FJ, Micke O, Haverkamp U, Willich N, Schüller P, Pötter R. Results of fast neutron therapy of adenoid cystic carcinoma of the salivary glands. Anticancer Res. 2000;20:3743–9.PubMed
8.
Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12:815–24.CrossRefPubMed
9.
Papaspyrou G, Hoch S, Rinaldo A, Rodrigo JP, Takes RP, van Herpen C, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck. 2010;33:905–11.CrossRefPubMed
10.
Samant S, van den Brekel MW, Kies MS, Wan J, Robbins KT, Rosenthal DI, et al. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck. 2011;34:1263–8.CrossRefPubMed
11.
Büchsenschütz K, Veit JA, Schuler PJ, Thierauf J, Laban S, Fahimi F, et al. Molecular approaches to systemic therapy of adenoid cystic carcinoma of the head and neck area. Laryngorhinootologie. 2014;93:657–64.CrossRefPubMed
12.
Westra WH. The surgical pathology of salivary gland neoplasms. Otolaryngol Clin N Am. 1999;32:919–43.CrossRef
13.
Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1999;125:149.CrossRefPubMed
14.
Coca-Pelaz A, Rodrigo JP, Bradley PJ, Vander Poorten V, Triantafyllou A, Hunt JL, et al. Adenoid cystic carcinoma of the head and neck – an update. Oral Oncol. 2015;51:652–61.CrossRefPubMed
15.
Huang M, Ma D, Sun K, Yu G, Guo C, Gao F. Factors influencing survival rate in adenoid cystic carcinoma of the salivary glands. Int J Oral Maxillofac Surg. 1997;26:435–9.CrossRefPubMed
16.
Ciccolallo L, Licitra L, Cantú G, Gatta G. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol. 2009;45:669–74.CrossRefPubMed
17.
Adams S, Baum RP, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18 F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med Mol Imaging. 1998;25:1255–60.CrossRef
18.
Wu S, Liu G, Chen R, Guan Y. Role of ultrasound in the assessment of benignity and malignancy of parotid masses. Dentomaxillofac Radiol. 2012;41:131–5.CrossRefPubMedPubMedCentral
19.
Kato H, Kanematsu M, Sakurai K, Mizuta K, Aoki M, Hirose Y, et al. Adenoid cystic carcinoma of the maxillary sinus: CT and MR imaging findings. Jpn J Radiol. 2013;31:744–9.CrossRefPubMed
20.
Freudenberg LS, Antoch G, Schütt P, Beyer T, Jentzen W, Müller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–9.CrossRefPubMed
21.
Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2012;39:852–63.CrossRefPubMed
22.
Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, et al. Dual tracer functional imaging of Gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT. Clin Nucl Med. 2014;39:e27–34.CrossRefPubMed
23.
Bhagat N, Zuckier LS, Hameed M, Cathcart C, Baredes S, Ghesani NV. Detection of recurrent adenoid cystic carcinoma with PET-CT. Clin Nucl Med. 2007;32:574–7.CrossRefPubMed
24.
Treglia G, Bertagna F, Ceriani L, Giovanella LA. Rare case of adenoid cystic carcinoma of the breast detected by 18F-FDG PET/CT. Revista Española de Medicina Nuclear e Imagen Molecular. 2015;34:205–6.PubMed
25.
Otsuka H, Graham MM, Kogame M, Nishitani H. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med. 2005;19:691–4.CrossRefPubMed
26.
Park CM, Goo JM, Lee HJ, Kim MA, Lee CH, Kang M-J. Tumors in the tracheobronchial tree: CT and FDG PET Features1. Radiographics. 2009;29:55–71.CrossRefPubMed
27.
Kim D, Kim W, Lee J, Ki Y, Lee B, Cho K, et al. Pretreatment maximum standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography as a predictor of distant metastasis in adenoid cystic carcinoma of the head and neck. Head Neck. 2015;38:755–61.CrossRefPubMed
28.
Bradley PJ. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg. 2004;12:127–32.CrossRefPubMed
29.
Spiro H, Distant R. Metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. 1997;174:495–8.CrossRefPubMed
30.
Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2-Fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope. 2005;115:1186–90.CrossRefPubMed
31.
Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K, et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiation Oncol Biol Phys. 2007;68:377–82.CrossRef
32.
Bradley PJ. Distant metastases from salivary glands cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:233–42.CrossRefPubMed
33.
Tewari A, Padma S, Sundaram P. Detection of atypical metastases in recurrent adenoid cystic carcinoma of parotid gland. J Can Res Ther. 2013;9:148.CrossRef
Metadata
Title
Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma
Authors
Verena Ruhlmann
Thorsten D. Poeppel
Johannes Veit
James Nagarajah
Lale Umutlu
Thomas K. Hoffmann
Andreas Bockisch
Ken Herrmann
Wolfgang Sauerwein
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3890-4

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Erratum

Erratum to: Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer

Research article

The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer

Study protocol

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)

Research article

Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo

Research article

Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma

Case report

Contrast-enhanced ultrasound of small cell carcinoma in urinary bladder: a case report and review of literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits